BTIG Affirms Regeneron (REGN) at 'Neutral' as ODYSSEY OUTCOMES Trial to Continue

BTIG affirms Regeneron Pharmaceuticals (Nasdaq: REGN) at Neutral after the company and Sanofi announced that the ongoing Praluent (alirocumab) ODYSSEY OUTCOMES trial will continue as planned, based on the recommendation of an independent Data Monitoring Committee (DMC) after it completed a second pre-specified interim analysis. The DMC will continue to monitor the ongoing safety and efficacy of Praluent as planned.

Analyst Dane Leone commented today: We were not expecting an early stop to the trial, but in tandem with limited differentiation of cardiovascular events within the Repatha trial, investors may remain cautious regarding the potential for success. Differentiation of cardiovascular outcomes remains a key potential driver for adoption of PCSK9 therapy relative to high dose statins, and will continue to be watched closely by the Street.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $1,030 at TD Cowen
• Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
• Tyler Tech (TYL) PT Raised to $500 at Oppenheimer